Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 977

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Open access
Smith, Matthew R., Hussain, Maha, Saad, Fred, Fizazi, Karim, Sternberg, Cora N., Crawford, E. David, Kopyltsov, Evgeny, Park, Chandler H., Alekseev, Boris, Montesa-Pino, Álvaro, Ye, Dingwei, Parnis, Francis, Cruz, Felipe, Tammela, Teuvo L.J., Suzuki, Hiroyoshi, Utriainen, Tapio, Fu, Cheng, Uemura, Motohide, Méndez-Vidal, María J., Maughan, Benjamin L., Joensuu, Heikki, Thiele, Silke, Li, Rui, Kuss, Iris, Tombal, Bertrand·2022·New England Journal of Medicine

Abstract

BACKGROUND: Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase survival among patients with metastatic, hormone-sensitive prostate cancer is unknown. METHODS: In this international, phase 3 trial, we randomly assigned patients with metastatic, hormone-sensitive prostate cancer in a 1:1 ratio to receive darolutamide (at a dose of 600 mg [two 300-mg tablets] twice daily) or matching placebo, both in combination with androgen-deprivation therapy and docetaxel. The primary end point was overall survival. RESULTS: The primary analysis involved 1306 patients (651 in the darolutamide group and 655 in the placebo group); 86.1% of the patients had disease that was metastatic at the time of the initial diagnosis. At the data cutoff date for the primary analysis (October 25, 2021), the risk of death was significantly lower, by 32.5%, in the darolutamide group than in the placebo group (hazard ratio 0.68; 95% confidence interval, 0.57 to 0.80; P<0.001). Darolutamide was also associated with consistent benefits with respect to the secondary end points and prespecified subgroups. Adverse events were similar in the two groups, and the incidences of the most common adverse events (occurring in ≥10% of the patients) were highest during the overlapping docetaxel treatment period in both groups. The frequency of grade 3 or 4 adverse events was 66.1% in the darolutamide group and 63.5% in the placebo group; neutropenia was the most common grade 3 or 4 adverse event (in 33.7% and 34.2%, respectively). CONCLUSIONS: In this trial involving patients with metastatic, hormone-sensitive prostate cancer, overall survival was significantly longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with placebo plus androgen-deprivation therapy and docetaxel, and the addition of darolutamide led to improvement in key secondary end points. The frequency of adverse events was similar in the two groups. (Funded by Bayer and Orion Pharma; ARASENS ClinicalTrials.gov number, NCT02799602.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2119115

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 977

Metadata

Authors
Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., Kopyltsov, E., Park, C. H., Alekseev, B., Montesa-Pino, Á., Ye, D., Parnis, F., Cruz, F., Tammela, T. L. J., Suzuki, H., Utriainen, T., Fu, C., Uemura, M., Méndez-Vidal, M. J., Maughan, B. L., Joensuu, H., Thiele, S., Li, R., Kuss, I., & Tombal, B.
Venue
New England Journal of Medicine
Published
2022-03-24
Volume
386
Issue
12
Pages
1132-1142
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4213140514
Cited by
977
References
19
FWCI
110.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. https://app.cochat.ai/papers/10.1056/nejmoa2119115
The paper
Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., Kopyltsov, E., Park, C. H., Alekseev, B., Montesa-Pino, Á., Ye, D., Parnis, F., Cruz, F., Tammela, T. L. J., Suzuki, H., Utriainen, T., Fu, C., Uemura, M., Méndez-Vidal, M. J., . . . Tombal, B. (2022). Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2119115

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.